

## PREFERRED SPECIALTY MANAGEMENT POLICY

- POLICY:** Ophthalmology – Vascular Endothelial Growth Factor Inhibitors – Ranibizumab Products Preferred Specialty Management Policy
- Byooviz™ (ranibizumab-nuna intravitreal injection - Biogen)
  - Cimerli™ (ranibizumab-eqrn intravitreal injection - Coherus)
  - Lucentis® (ranibizumab intravitreal injection - Genentech)

**REVIEW DATE:** 04/24/2024

---

### OVERVIEW

Byooviz and Cimerli are interchangeable biosimilars to Lucentis, indicating no clinically meaningful differences in safety and effectiveness and the same mechanism of action, route of administration, and dosage form as Lucentis. However, minor differences in clinically inactive components are allowed.

Cimerli and Lucentis have identical indications; Byooviz is indicated for three of the five indications. Table 1 provides the labeled indications for the three products.

**Table 1. FDA-Approved Indications.**

### POLICY STATEMENT

This Preferred Specialty Management program has been developed to encourage the use of a Preferred Product. For all medications (Preferred and Non-Preferred), the patient is required to meet the respective standard *Prior Authorization Policy* criteria. The program also directs the patient to try two Preferred Products prior to the approval of a Non-Preferred Product. Requests for the Non-Preferred Product will also be reviewed using the exception criteria (below). If the patient meets the standard *Ophthalmology – Vascular Endothelial Growth Factor Inhibitors – Ranibizumab Products Prior Authorization Policy* criteria but has not tried two Preferred Products, a review will be offered for the Preferred Products using the respective standard *Prior Authorization Policy* criteria. All approvals are provided for 1 year in duration.

**Automation:** None.

**Preferred Products:** Byooviz and Cimerli  
**Non-Preferred Product:** Lucentis

## **RECOMMENDED EXCEPTION CRITERIA**

### **REFERENCES**

1. Byooviz™ [prescribing information]. Cambridge, MA: Biogen; October 2023
2. Cimerli™ [prescribing information]. Redwood City, CA: Coherus BioSciences; November 2022.
3. Lucentis® [prescribing information]. South San Francisco, CA: Genentech; February 2024.